Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bray

Showing results (231-240 of 247) with videos related to

Pageof 25
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumorsJennifer R Diamond, Bruno R Bastos, Ryan J Hansen, et al.
Cancer Gene Therapy|August 23, 2024
Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome amplificationChristopher Zhang, Benson Z Wu, Caterina Di Ciano-Oliveira, et al.
Science Advances|September 7, 2022
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER<sup>+</sup> breast cancer with mitotic aberrationsIsabel Soria-Bretones, Kelsie L Thu, Jennifer Silvester, et al.
Leukemia|December 19, 2023
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasmsTracy Murphy, Jacqueline M Mason, Brian Leber, et al.
Bioorganic & Medicinal Chemistry Letters|June 24, 2016
Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTKRadoslaw Laufer, Sze-Wan Li, Yong Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2024
Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair-Deficient Uterine LeiomyosarcomaHorace H Y Lee, Kin Long Chow, Ho Shing Wong, et al.
Science (New York, N.Y.)|July 25, 2020
Simultaneous cross-evaluation of heterogeneous <i>E. coli</i> datasets via mechanistic simulationDerek N Macklin, Travis A Ahn-Horst, Heejo Choi, et al.
Clinical Biochemistry|September 28, 2014
Absolute and relative changes (delta) in troponin I for early diagnosis of myocardial infarction: Results of a prospective multicenter trialAlan B Storrow, Richard M Nowak, Deborah B Diercks, et al.
Nature Immunology|August 20, 2003
The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responsesWoong-Kyung Suh, Beata U Gajewska, Hitoshi Okada, et al.
ACS Medicinal Chemistry Letters|July 21, 2016
Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer AgentYong Liu, Radoslaw Laufer, Narendra Kumar Patel, et al.
Pageof 25

Showing results (231-240 of 247) with videos related to

Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumorsJennifer R Diamond, Bruno R Bastos, Ryan J Hansen, et al.
Cancer Gene Therapy|August 23, 2024
Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome amplificationChristopher Zhang, Benson Z Wu, Caterina Di Ciano-Oliveira, et al.
Science Advances|September 7, 2022
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER<sup>+</sup> breast cancer with mitotic aberrationsIsabel Soria-Bretones, Kelsie L Thu, Jennifer Silvester, et al.
Leukemia|December 19, 2023
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasmsTracy Murphy, Jacqueline M Mason, Brian Leber, et al.
Bioorganic & Medicinal Chemistry Letters|June 24, 2016
Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTKRadoslaw Laufer, Sze-Wan Li, Yong Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2024
Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair-Deficient Uterine LeiomyosarcomaHorace H Y Lee, Kin Long Chow, Ho Shing Wong, et al.
Science (New York, N.Y.)|July 25, 2020
Simultaneous cross-evaluation of heterogeneous <i>E. coli</i> datasets via mechanistic simulationDerek N Macklin, Travis A Ahn-Horst, Heejo Choi, et al.
Clinical Biochemistry|September 28, 2014
Absolute and relative changes (delta) in troponin I for early diagnosis of myocardial infarction: Results of a prospective multicenter trialAlan B Storrow, Richard M Nowak, Deborah B Diercks, et al.
Nature Immunology|August 20, 2003
The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responsesWoong-Kyung Suh, Beata U Gajewska, Hitoshi Okada, et al.
ACS Medicinal Chemistry Letters|July 21, 2016
Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer AgentYong Liu, Radoslaw Laufer, Narendra Kumar Patel, et al.
Pageof 25